Disclosure information not submitted.
Too Little, Too Late? Rethinking Primary Prevention Strategies for ASCVD This activity is multi-supported by educational grants from Arrowhead Pharmaceuticals, Inc., Esperion Therapeutics, Inc., and Novartis Pharmaceuticals Corporation
Too Little, Too Late? Rethinking Primary Prevention Strategies for ASCVD
This activity is multi-supported by educational grants from Arrowhead Pharmaceuticals, Inc., Esperion Therapeutics, Inc., and Novartis Pharmaceuticals Corporation
Saturday, October 17, 20269:05 AM - 9:25 AM EDT
Challenging Lipid Management Cases with Expert Panel Discussion and Audience Q&A
Saturday, October 17, 202612:00 PM - 1:25 PM EDT
